Skip to content

Study · Observational study · n = 148 · 2025

8 results

Liraglutide in the management of obesity: real world data (Portugal).

Tavares Bello C, Redondo Carvalho I, Martins A, Martins AF, Wessling A, Macedo D, Martins D, Fernandes C, Sobral DO Rosário F

Minerva endocrinology16 Jul 2024Cited by 1 (Europe PMC)

PMID39012306 (opens in a new tab)DOI10.23736/s2724-6507.24.04161-7 (opens in a new tab)PepBankPUB-39012306
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studySafety outcome

    Among adults with overweight or obesity without diabetes or prior bariatric surgery treated with liraglutide, 7 withdrawals were attributed to gastrointestinal intolerance.

    In plain wordsAmong adults without diabetes treated with liraglutide for overweight or obesity, 7 stopped because of gastrointestinal intolerance.

    Peptide
    Liraglutide
    Outcome
    Not applicableGastrointestinal intolerance leading to withdrawal
    Study

    n = 148

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Withdrawals
    7
    gastrointestinal intolerance

    Source sentences

    Summary
    The reasons for liraglutide withdrawal were gastrointestinal intolerance (7), medication cost (2), inefficacy (10) and physician instructions (1).
    6 context sentences
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.
    Summary · context
    One hundred forty-eight patients (85.8% females) with a mean age of 48.7±11.9 years were treated with liraglutide.
  2. 02HumanObservational studyOther

    Among adults treated with liraglutide for overweight or obesity, 85.8% were still taking liraglutide at the last appointment.

    In plain wordsAmong adults treated with liraglutide, 85.8% were still taking it at the last visit.

    Peptide
    Liraglutide
    Outcome
    Not applicableContinuation of liraglutide at last appointment
    Study

    n = 148

    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated

    Measurements

    Still taking liraglutide
    85.8%
    last appointment

    Source sentences

    Summary
    At the last appointment, 85.8% were still taking liraglutide.
    6 context sentences
    Summary · context
    One hundred forty-eight patients (85.8% females) with a mean age of 48.7±11.9 years were treated with liraglutide.
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.
  3. 03HumanObservational studyOther

    Among adults treated with liraglutide for overweight or obesity, 2 withdrawals were attributed to medication cost.

    In plain wordsAmong adults treated with liraglutide, 2 stopped because of medication cost.

    Peptide
    Liraglutide
    Outcome
    Not applicableWithdrawal due to medication cost
    Study

    n = 148

    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated

    Measurements

    Withdrawals
    2 patients
    medication cost

    Source sentences

    Summary
    The reasons for liraglutide withdrawal were gastrointestinal intolerance (7), medication cost (2), inefficacy (10) and physician instructions (1).
    6 context sentences
    Summary · context
    One hundred forty-eight patients (85.8% females) with a mean age of 48.7±11.9 years were treated with liraglutide.
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.
  4. 04HumanObservational studyOther

    Among adults treated with liraglutide for overweight or obesity, 10 withdrawals were attributed to inefficacy.

    In plain wordsAmong adults treated with liraglutide, 10 stopped because treatment was ineffective.

    Peptide
    Liraglutide
    Outcome
    Not applicableWithdrawal due to inefficacy
    Study

    n = 148

    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated

    Measurements

    Withdrawals
    10 patients
    inefficacy

    Source sentences

    Summary
    The reasons for liraglutide withdrawal were gastrointestinal intolerance (7), medication cost (2), inefficacy (10) and physician instructions (1).
    6 context sentences
    Summary · context
    One hundred forty-eight patients (85.8% females) with a mean age of 48.7±11.9 years were treated with liraglutide.
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.
  5. 05HumanObservational studyOther

    Among adults treated with liraglutide for overweight or obesity, 1 withdrawal was attributed to physician instructions.

    In plain wordsAmong adults treated with liraglutide, 1 stopped on physician instructions.

    Peptide
    Liraglutide
    Outcome
    Not applicableWithdrawal due to physician instructions
    Study

    n = 148

    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated

    Measurements

    Withdrawals
    1 patient
    physician instructions

    Source sentences

    Summary
    The reasons for liraglutide withdrawal were gastrointestinal intolerance (7), medication cost (2), inefficacy (10) and physician instructions (1).
    6 context sentences
    Summary · context
    One hundred forty-eight patients (85.8% females) with a mean age of 48.7±11.9 years were treated with liraglutide.
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.
  6. 06HumanObservational studyEfficacy outcome

    Among adults with overweight or obesity without diabetes or prior bariatric surgery who continued liraglutide, mean weight loss was 7.6 kg (7.9%).

    In plain wordsAmong adults without diabetes who continued liraglutide for overweight or obesity, average weight loss was 7.6 kg.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    7.6 kg
    patients still taking liraglutide
    Weight loss
    7.9%
    patients still taking liraglutide

    Source sentences

    Summary
    Among patients still taking liraglutide, mean weight loss was 7.6 kg (7.9%), with significantly greater losses in patients treated for more than 6 months (8.6kg vs. 6.2 kg, P=0.016).
    5 context sentences
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.
  7. 07HumanObservational studyEfficacy outcome

    Among adults with overweight or obesity continuing liraglutide, treatment beyond 6 months was linked to greater weight-loss magnitude than shorter treatment (8.6 versus 6.2 kg; P=0.016).

    In plain wordsAmong adults with overweight or obesity continuing liraglutide, treatment beyond 6 months was linked to greater weight loss than shorter treatment.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight-loss magnitude by treatment duration
    Study

    n: not reported in source

    Comparator
    Patients with shorter liraglutide treatment
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    8.6 kg
    more than 6 months; P=0.016 versus shorter treatment
    Weight loss
    6.2 kg
    comparison group with shorter treatment

    Source sentences

    Summary
    Among patients still taking liraglutide, mean weight loss was 7.6 kg (7.9%), with significantly greater losses in patients treated for more than 6 months (8.6kg vs. 6.2 kg, P=0.016).
    5 context sentences
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.
  8. 08HumanObservational studyEfficacy outcome

    Among adults continuing liraglutide, obesity was linked to greater weight-loss magnitude than overweight despite similar treatment duration (8.3 versus 4.5 kg; P=0.028).

    In plain wordsAmong adults without diabetes who continued liraglutide, weight loss was greater in obesity than overweight.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight-loss magnitude by baseline weight status
    Study

    n: not reported in source

    Comparator
    Patients with overweight
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    8.3 kg
    obesity
    Weight loss
    4.5 kg
    overweight

    Source sentences

    Summary
    Patients with obesity lost significantly more weight than overweight patients (8.3 kg vs. 4.5 kg, P=0.028), despite similar treatment duration.
    5 context sentences
    Summary · context
    Retrospective, longitudinal observational study.
    Summary · context
    Inclusion criteria were adult patients (>18 years old) with obesity (BMI>30 kg/m2) or overweight (≥27 kg/m2) with at least one obesity related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease) with at least three months of liraglutide treatment.
    Summary · context
    Diabetes diagnosis and prior bariatric surgery were exclusion criteria.
    Summary · context
    Demographic and clinical variables were included and weight was recorded before and after at least 3 months of liraglutide treatment.
    Summary · context
    The authors report on the experience of a University Hospital Endocrine Clinic in the management of patients with overweight and obesity with liraglutide on top of lifestyle intervention.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.